Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: A randomised phase II study

British Journal of Cancer

Volumn 107, Issue 3, 2012, Pages 435-441

  Roy, A ^a   Cunningham, D ^a   Hawkins, R ^b   Sorbye H ^c   Adenis, A ^d   Barcelo, J R ^e   Lopez Vivanco, G ^e   Adler, G ^f   Canon, J L ^g   Lofts, F ^h   Castanon, C ⁱ   Fonseca, E ⁱ   Rixe, O ^j   Aparicio, J ^k   Cassinello, J ^l   Nicolson, M ^m   Mousseau, M ⁿ   Schalhorn, A ^o   D'Hondt, L ^p   Kerger, J ^p   Hossfeld, D K ^q   Garcia Giron, C ^r   Rodriguez, R ^s   Schoffski, P ^t   Misset, J L ^u   more..

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d CENTRE OSCAR LAMBRET   (France)

^e HOSPITAL DE CRUCES   (Spain)

^f UNIVERSITY OF ULM   (Germany)

^g Grand Hospital de Charleroi   (Belgium)

^h ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

ⁱ HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^k HOSPITAL UNIVERSITARIO LA FE   (Spain)

^l HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^m ABERDEEN ROYAL INFIRMARY   (United Kingdom)

ⁿ GRENOBLE UNIVERSITY HOSPITAL   (France)

^o LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^p UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^q UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^r HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

^s Hospital General Yagüe ^*  (Spain)

^t UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^u SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

5 fluorouracil; docetaxel; irinotecan; oesophago gastric cancer

Indexed keywords

DOCETAXEL; FLUOROURACIL; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; ESOPHAGUS CANCER; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; STOMACH CANCER; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; TAXOIDS;

EID: 84864371155     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.286     Document Type: Article

References (29)

1. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral Filho S, Majlis A, Assadourian S, Van Cutsem E (2005) Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23(24): 5660-5667
2. Assersohn L, Brown G, Cunningham D, Ward C, Oates J, Waters JS, Hill ME, Norman AR (2004) Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol 15(1): 64-69
3. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742): 687-697
4. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10(11): 1063-1069
5. Constenla M, Garcia-Arroyo R, Lorenzo I, Carrete N, Campos B, Palacios P (2002) Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study. Gastric Cancer 5(3): 142-147
6. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1): 36-46
7. Dank M, Zaluski J, Barone C, Valvere V, Peschel C,Wenczl M, Goker E, Risse M-L, Awad L, Bugat R (2005) Randomized phase 3 trial of irinotecan (CPT-11) +5FU/folinic acid (FA) vs CDDP +5FU in 1st-line advanced gastric cancer patients. ASCO Meeting Abstracts 23(16-suppl): 4003
8. Giordano KF, Jatoi A, Stella PJ, Foster N, Tschetter LK, Alberts SR, Dakhil SR, Mailliard JA, Flynn PJ, Nikcevich DA (2006) Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 17(4): 652-656
9. Hawkes E, Okines AF, Papamichael D, Rao S, Ashley S, Charalambous H, Koukouma A, Chau I, Cunningham D (2011) Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. Eur J Cancer 47(8): 1146-1151
10. Jatoi A, Tirona MT, Cha SS, Alberts SR, Rowland KM, Morton RF, Nair S, Kardinal CG, Stella PJ, Mailliard JA, Sargen D, Goldberg RM (2002) A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. Int J Gastrointest Cancer 32(2-3): 115-123
11. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90
12. Kang JH, Lee SI, Lim do H, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH (2012) Salvage chemotherapy for pretreated gastric cancer: a randomized phase iii trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30(13): 1513-1518
13. Kim SH, Lee GW, Go SI, Cho SH, Kim HJ, Kim HG, Kang JH (2010) A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidinebased regimen. Am J Clin Oncol 33(6): 572-576
14. Kohne CH, Catane R, Klein B, Ducreux M, Thuss-Patience P, Niederle N, Gips M, Preusser P, Knuth A, Clemens M, Bugat R, Figer I, Shani A, Fages B, Di Betta D, Jacques C, Wilke HJ (2003) Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial. Br J Cancer 89(6): 997-1001
15. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1): 207-214
16. Park SR, Chun JH, Yu MS, Lee JH, Ryu KW, Choi IJ, Kim CG, Lee JS, Kim YW, Bae JM, Kim HK (2006) Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma. Br J Cancer 94(10): 1402-1406
17. Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bukki J, Gorbunova V, Valvere V, Zaluski J, Biakhov M, Zuber E, Jacques C, Bugat R (2004) Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Ann Oncol 15(12): 1773-1781
18. Shah MA, Shibata S, Stoller RG, Kemeny M, Ritch PS, Krishnamurthi SS, Su YB, Janjigian YY, Capanu M, Kelsen DP, MSKCC Gastric Cancer Consortium (2010) Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE). ASCO Meeting Abstracts 28(15-suppl): 4014
19. Sym SJ, Chang HM, Kang HJ, Lee SS, Ryu MH, Lee JL, Kim TW, Yook JH, Oh ST, Kim BS, Kang YK (2008) A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer. Cancer Chemother Pharmacol 63(1): 1-8
20. Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, Stockler M, Gebski V, Zalcberg J (2010) Randomised, noncomparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer 102(3): 475-481
21. Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P (2011) Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer 47(15): 2306-2314
22. Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, Hennesser D, Micheel S, Pink D, Scholz C, Dorken B, Reichardt P (2005) Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 23(3): 494-501
23. Van Cutsem E, Boni C, Tabernero J, Massuti B, Richards DA, Prenen H, Steinberg I, Rougier P (2011a) Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer. ASCO Meeting Abstracts 29(15-suppl): 4018
24. Van Cutsem E, Dicato M, Geva R, Arber N, Bang Y, Benson A, Cervantes A, Diaz-Rubio E, Ducreux M, Glynne-Jones R, Grothey A, Haller D, Haustermans K, Kerr D, Nordlinger B, Marshall J, Minsky BD, Kang YK, Labianca R, Lordick F, Ohtsu A, Pavlidis N, Roth A, Rougier P, Schmoll HJ, Sobrero A, Tabernero J, Van de Velde C, Zalcberg J (2011b) The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010. Ann Oncol 22(suppl 5): v1-v9
25. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24(31): 4991-4997
26. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, Fleig WE (2010) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 3: CD004064
27. Wesolowski R, Lee C, Kim R (2009) Is there a role for secondline chemotherapy in advanced gastric cancer? Lancet Oncol 10(9): 903-912
28. Yamaguchi K, Shimamura T, Hyodo I, Koizumi W, Doi T, Narahara H, Komatsu Y, Kato T, Saitoh S, Akiya T, Munakata M, Miyata Y, Maeda Y, Takiuchi H, Nakano S, Esaki T, Kinjo F, Sakata Y (2006) Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 94(12): 1803-1808
29. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Takiyama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J, Nishiyama M (2006) Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12(11 part 1): 3402-3407